Inclusion Criteria:  Individuals 65 and older English speaking Male or female Current insomnia (Insomnia Severity Index score ≥ 8 during the baseline period). Recent suicidal ideation (endorsement of Items 1 or 2 of the Columbia Suicide Severity Rating Scale - Suicidal Ideation subscale within the past month). All participants must consent to a release of information between the research team and their treatment provider (either their prescribing psychiatrist, their masters-level non-trainee therapist, or their doctoral-level psychologist).  Exclusion Criteria:  Diagnosis of bipolar disorder, any psychotic disorder, or other serious mental illness deemed a contraindication for dCBT-I. If a subject is taking psychotropic medication(s) (e.g., antidepressants, hypnotics), they should not have changed the dose within the past 6 weeks and should agree to not change the dose during the trial. If a subject is not taking psychotropic medication(s), they should be medication free for at least 6 weeks and should agree to not start a new medication for the duration of the trial. Suspicion or evidence of untreated sleep apnea, restless legs syndrome, or other untreated sleep disorder requiring treatment by a physician. Uncontrolled or unstable chronic medical conditions Life expectancy of less than 1 year as determined by record review and intake interview. Cognitive impairment sufficient to impair delivery or retention of dCBT-I as indicated by the Short Blessed Test. Are currently or are planning to work evening/overnight shifts. Lack of access to internet or technology necessary to engage in digital therapy. Participants who have been hospitalized for a suicide attempt or severe suicidal ideation, or who endorse any intent to commit suicide in the last 3 months must receive assent/approval from their treatment provider to participate, in addition to providing a release of information for the research team to communicate with the treatment team.